Researchers assessed EUS-RFA in 26 patients with unresectable pancreatic ductal adenocarcinoma, showing technical success in all cases and no major adverse events. Six months post-EUS-RFA, 42.3% of patients had improved overall survival and significant performance status enhancement. Tumor reduction and post-treatment necrotic areas were observed, while metastatic disease negatively impacted survival. EUS-RFA proved safe and potentially beneficial in locally advanced and non-metastatic cases, suggesting its role as targeted therapy for unresectable pancreatic adenocarcinoma.
Journal Article by Robles-Medranda C, Del Valle R (…) Tabacelia D et 15 al. in Gastrointest Endosc
Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.